Exscientia plc: Business Overview, Financials & Competitive Analysis
Exscientia was a pioneering AI-driven drug discovery platform that used generative AI and machine learning to design novel therapeutic compounds faster and more cost-effectively than traditional methods. The company a...
Get the Latest Exscientia plc Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeExscientia plc Overview
Pro stress-test →Exscientia was a pioneering AI-driven drug discovery platform that used generative AI and machine learning to design novel therapeutic compounds faster and more cost-effectively than traditional methods. The company achieved a landmark IPO in October 2021 (raising $510M), advanced the first AI-designed drugs into human clinical trials, and established partnerships with pharmaceutical giants including Sanofi and Bristol-Myers Squibb. However, the company ceased to exist as an independent entity on November 20, 2024, when it was acquired by and integrated into Recursion Pharmaceuticals.
Strategic Profile
Pro stress-test →Exscientia's differentiation lay in its precision medicine platform and demonstrated ability to achieve 10X productivity gains in drug candidate creation while reducing preclinical research costs. The company deployed generative AI via its DesignStudio to intelligently 'learn' across chemical space rather than relying on conventional high-throughput screening. Post-acquisition, Exscientia operates as Recursion's wholly-owned subsidiary, forming a vertically-integrated AI-enabled drug discovery and development platform.
Competitive Landscape
Pro stress-test →Before its acquisition, Exscientia competed with other AI-driven drug discovery platforms including Schrodinger (NASDAQ: SDGR), X-37, insitro, Numerion Labs, Iambic, and Genesis Molecular AI. These companies target the same computational drug discovery market, using machine learning and AI to accelerate preclinical development and reduce costs. The acquisition by Recursion reflects industry consolidation as pure-play AI drug discovery platforms seek scale through integration with clinical development and manufacturing capabilities.
Industry Context
Exscientia plc operates in Drug Discovery Services.
Key facts
Founded: 2012 · Headquarters: Oxford, UK · Employees: Unknown · Revenue: Estimated; pre-acquisition partnerships generated approximately $450M in upfront and milestone payments combined with Recursion · Market cap: N/A (private subsidiary as of November 2024)